Cargando…

Gonadotropin-Releasing Hormone Agonists Sensitize, and Resensitize, Prostate Cancer Cells to Docetaxel in a p53-Dependent Manner

Gonadotropin-releasing hormone (GnRH) receptors are expressed in prostate cancer, specifically in the most aggressive stage of the tumor (castration-resistant prostate cancer, CRPC) for which the standard treatment, docetaxel-based chemotherapy, can only improve the median survival time by few month...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moretti, Roberta M., Marelli, Marina Montagnani, Taylor, Deanne M., Martini, Paolo G. V., Marzagalli, Monica, Limonta, Patrizia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983111/ https://www.ncbi.nlm.nih.gov/pubmed/24722580 http://dx.doi.org/10.1371/journal.pone.0093713

Ejemplares similares

Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions
por: Fontana, Fabrizio, et al.
Publicado: (2020)

Estrogen Receptor β Agonists Differentially Affect the Growth of Human Melanoma Cell Lines
por: Marzagalli, Monica, et al.
Publicado: (2015)

Dual role of autophagy on docetaxel-sensitivity in prostate cancer cells
por: Cristofani, Riccardo, et al.
Publicado: (2018)

Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility
por: Marzagalli, Monica, et al.
Publicado: (2016)

Role of Endoplasmic Reticulum Stress in the Anticancer Activity of Natural Compounds
por: Limonta, Patrizia, et al.
Publicado: (2019)

δ‐Tocotrienol induces apoptosis, involving endoplasmic reticulum stress and autophagy, and paraptosis in prostate cancer cells
por: Fontana, Fabrizio, et al.
Publicado: (2019)

Vitamin E δ-tocotrienol triggers endoplasmic reticulum stress-mediated apoptosis in human melanoma cells
por: Montagnani Marelli, Marina, et al.
Publicado: (2016)

Targeting melanoma stem cells with the Vitamin E derivative δ-tocotrienol
por: Marzagalli, Monica, et al.
Publicado: (2018)

Gonadotropin releasing hormone agonists: Expanding vistas
por: Magon, Navneet
Publicado: (2011)

Necroptosis Induced by Delta-Tocotrienol Overcomes Docetaxel Chemoresistance in Prostate Cancer Cells
por: Montagnani Marelli, Marina, et al.
Publicado: (2023)

Gonadotropin-releasing hormone agonist-induced pituitary apoplexy
por: Keane, Fergus, et al.
Publicado: (2016)

Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
por: Shiasi Arani, Kobra, et al.
Publicado: (2015)

Gonadotropin-Releasing Hormone Agonist Induced Pituitary Apoplexy
por: Yu, Xiaoling, et al.
Publicado: (2021)

Agonist-induced internalization and downregulation of gonadotropin-releasing hormone receptors
por: Finch, Ann R., et al.
Publicado: (2009)

The role of gonadotropin-releasing hormone agonists in female fertility preservation
por: Lee, Jae Hoon, et al.
Publicado: (2021)

Desensitization, Trafficking, and Resensitization of the Pituitary Thyrotropin-Releasing Hormone Receptor
por: Hinkle, Patricia M., et al.
Publicado: (2012)

A Case of Thromboembolism After Injection of Gonadotropin-releasing Hormone Agonist
por: Zhou, Feng, et al.
Publicado: (2016)

Gonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention
por: Castillo, Juan Carlos, et al.
Publicado: (2020)

Is gonadotropin-releasing hormone agonist usage really leading to thyroid dysfunction?
por: Yilmaz, Nafiye, et al.
Publicado: (2019)

Pituitary Apoplexy Secondary to Gonadotropin-Releasing Hormone Agonist for Breast Cancer
por: Mastandrea, Katherine, et al.
Publicado: (2023)

Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles
por: Tehraninejad, Ensieh Sh., et al.
Publicado: (2010)

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018)

A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
por: Hoseini, Fatemeh Sadat, et al.
Publicado: (2014)

Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Has the Same Effect as Gonadotropin-Releasing Hormone Agonist Injections in Terms of Preparation for Transcervical Resection Myomectomy
por: Ito, Mika, et al.
Publicado: (2022)

Final Oocyte Maturation in Assisted Reproduction with Human Chorionic Gonadotropin and Gonadotropin-releasing Hormone agonist (Dual Trigger)
por: de Oliveira, Sofia Andrade, et al.
Publicado: (2016)

Effects of gonadotropin-releasing hormone agonist on human chorionic gonadotropin activity in granulosa cells of immature female rats
por: TUNGMAHASUK, Doungrut, et al.
Publicado: (2017)

Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves the outcome of intrauterine insemination
por: Halim, Binarwan, et al.
Publicado: (2022)

Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer
por: Choi, Seungtaek, et al.
Publicado: (2011)

Thyroid Dysfunction Associated with Administration of the Long-Acting Gonadotropin-Releasing Hormone Agonist
por: Han, Eun Jin, et al.
Publicado: (2013)

Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells
por: Scaruffi, Paola, et al.
Publicado: (2019)

Quercetin Inhibits Lef1 and Resensitizes Docetaxel-Resistant Breast Cancer Cells
por: Prieto-Vila, Marta, et al.
Publicado: (2020)

Recurrent Endometrial Stromal Sarcoma: Treatment with a Progestin and Gonadotropin Releasing Hormone Agonist
por: duPont, Nefertiti Chianti, et al.
Publicado: (2010)

Increased Risk of Pneumonia in Patients Receiving Gonadotropin-Releasing Hormone Agonists for Prostate Cancer
por: Chung, Shiu-Dong, et al.
Publicado: (2014)

Pseudotumour Cerebri Presentation in a Child Under the Gonadotropin-Releasing Hormone Agonist Treatment
por: Gül, Ülkü, et al.
Publicado: (2016)

Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist
por: Mohamad, Nur-Vaizura, et al.
Publicado: (2018)

Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty
por: Kim, Hye Ryun, et al.
Publicado: (2017)

The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty
por: Yoon, Jong Wan, et al.
Publicado: (2017)

Myxedema Coma Following the Administration of Gonadotropin-releasing Hormone Agonist Complicated by Acute Pancreatitis
por: Gocho, Naoki, et al.
Publicado: (2018)

Gonadotropin-releasing hormone agonist triggering of oocyte maturation in assisted reproductive technology cycles
por: Türkgeldi, Engin, et al.
Publicado: (2015)

Transient impact of paclitaxel on mouse fertility and protective effect of gonadotropin-releasing hormone agonist
por: Ma, Nieying, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kqo7ro7e6c3lvnaacjefe8irq8